Technical Analysis for BNTC - Benitec Biopharma Limited

Grade Last Price % Change Price Change
C 4.74 -9.02% -0.47
BNTC closed down 9.02 percent on Thursday, April 15, 2021, on 9 percent of normal volume. It was able to bounce off of its 200 day moving average, an important long-term support line.

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Strong Up Up Down
Historical BNTC trend table...

Date Alert Name Type % Chg
Fell Below 20 DMA Bearish 0.00%
200 DMA Support Bullish 0.00%
Wide Bands Range Expansion 0.00%
20 DMA Support Bullish -9.02%
Wide Bands Range Expansion -9.02%
200 DMA Support Bullish -3.27%
20 DMA Support Bullish -3.27%
Narrow Range Bar Range Contraction -3.27%
NR7 Range Contraction -3.27%
Wide Bands Range Expansion -3.27%
Older End-of-Day Signals for BNTC ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
200 DMA Support about 13 hours ago
Fell Below Previous Day's Low about 14 hours ago
20 DMA Support about 17 hours ago
Down 5% about 18 hours ago
Fell Below 20 DMA about 18 hours ago
View Earlier Intraday Alerts

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.


Benitec Biopharma Limited Description

Benitec Biopharma Limited, a biotechnology company, develops novel treatments for chronic and life-threatening conditions based on its gene silencing technology, DNA-directed RNA interference (ddRNAi). The company's ddRNAi technology provides novel therapeutics to treat a range of human medical diseases and conditions, such as hepatitis C, hepatitis B, wet age-related macular degeneration, cancer-associated pain, drug resistant lung cancer, and oculopharyngeal muscular dystrophy (OPMD). Its pipeline of in-house and partnered therapeutic programs include TT-034 for hepatitis C; Tribetarna for the treatment of chemotherapy resistant non-small cell lung cancer; Hepbarna for Hepatitis B; and Pabparna for the treatment of OPMD. The company also licenses its ddRNAi technology to biopharmaceutical companies for the clinical applications comprising HIV/AIDS, retinitis pigmentosa, and Huntington's disease. Benitec Biopharma Limited was founded in 1997 and is based in Sydney, Australia.


Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Keywords: Biotechnology Biopharmaceutical Biology Pain Genetics Chemotherapy Small Cell Lung Cancer Macular Degeneration Related Macular Degeneration Hepatitis B Gene Expression Dystrophy Genetic Engineering Hepatitis C Muscular Dystrophy Wet Age Related Macular Degeneration Huntington's Disease HIV/Aids Retinitis RNA Rna Interference Retinitis Pigmentosa Clinical Applications Gene Silencing Ai Technology Chronic And Life Threatening Conditions Oculopharyngeal Muscular Dystrophy

Is BNTC a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 17.39
52 Week Low 2.3
Average Volume 3,216,842
200-Day Moving Average 4.72
50-Day Moving Average 4.28
20-Day Moving Average 4.95
10-Day Moving Average 5.02
Average True Range 0.79
ADX 40.24
+DI 32.92
-DI 14.76
Chandelier Exit (Long, 3 ATRs ) 8.14
Chandelier Exit (Short, 3 ATRs ) 5.21
Upper Bollinger Band 7.41
Lower Bollinger Band 2.48
Percent B (%b) 0.46
BandWidth 99.60
MACD Line 0.25
MACD Signal Line 0.30
MACD Histogram -0.0519
Fundamentals Value
Market Cap 20.88 Million
Num Shares 4.41 Million
EPS -0.82
Price-to-Earnings (P/E) Ratio -5.78
Price-to-Sales 26.04
Price-to-Book 1.63
PEG Ratio 0.00
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 5.70
Resistance 3 (R3) 5.79 5.57 5.54
Resistance 2 (R2) 5.57 5.32 5.52 5.49
Resistance 1 (R1) 5.15 5.17 5.04 5.06 5.43
Pivot Point 4.93 4.93 4.87 4.88 4.93
Support 1 (S1) 4.51 4.68 4.40 4.42 4.05
Support 2 (S2) 4.29 4.53 4.24 3.99
Support 3 (S3) 3.87 4.29 3.94
Support 4 (S4) 3.78